Echo Therapeutics, Inc. Achieves Wireless Mobile Communication Milestone
Non-Invasive Continuous Glucose Monitor Can Transmit Data to any Mobile Platform
ISELIN, N.J., March 30, 2015 /PRNewswire/ -- Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive continuous glucose monitoring and associated technologies, today announced that it has achieved its wireless mobile communication milestone, making it now possible for its continuous glucose sensor to transmit data to any mobile platform. This achievement marks the first key step in the strategic transformation of the Company's technology from a hospital-based medical system to a consumer product in both the wearable-health and diabetes segments.
Echo's Research & Development team created a new architecture to communicate wirelessly to mobile devices, including smartphones, using Bluetooth Low Energy (BLE) connectivity, keeping power consumption and cost to a minimum. Echo also developed a mobile application to demonstrate the transmitted glucose information on a smartphone. This new system leverages the progress made recently in both the skin preparation and glucose sensing technology and is currently being evaluated using in-house clinical feasibility studies. The Company received Institutional Review Board (IRB) approval for the clinical trial protocol and has commenced testing of these advancements.
"This milestone, announced in our recent webcast, is an important and critical first step forward for Echo as the application of our continuous glucose monitoring technology transitions to a consumer product. Importantly, the smartphone connectivity and mobile application now provides the ability to demonstrate our technology to potential partners," said Scott W. Hollander, Echo's President and CEO. "We look forward to updating shareholders with future advancements in the achievement of our goal of combining an advanced glucose sensor system with wireless and low-power communications into a small and flexible package."
About Echo Therapeutics
Echo Therapeutics is developing its proprietary, non-invasive, wireless, continuous glucose monitoring system for initial use in the fitness, weight loss and personal lifestyle wearable-health space. A longer-term opportunity also exists in the outpatient diabetes and hospital settings. Echo also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.
Cautionary Statement Regarding Forward Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.
For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104
Connect With Us:
- Visit our website at www.echotx.com
- Follow us on Twitter at www.twitter.com/echotx
- Join us on Facebook at www.facebook.com/echotx
SOURCE Echo Therapeutics, Inc.
Share this article